READY-TO-USE PEFLOXACIN INFUSION FOR SURGICAL PROPHYLAXIS

The efficacy of pefloxacin in preventing postsurgical infection was de monstrated in an open, comparative, randomized clinical trial. The 120 evaluable patients were divided into four groups of 30 each. Group A served as controls. Groups B, C, and D received one, two, and six dose s, respectively, of pefloxacin 400 mg in 100-mL solution as an intrave nous infusion. The majority of treated patients benefited from pefloxa cin therapy, with only 3% to 7% developing infection. In contrast, 20% of the placebo group developed infection within 5 days after surgery. Two of the 90 treated patients experienced mild side effects. One to six doses of ready-to-use pefloxacin infusion may be administered safe ly to provide antibacterial coverage during surgery.